Welcome back to Market on Close. I'm Sam Bardis live from the floor of the New York Stock Exchange. Shares of Revolution Medicines are rallying to an all-time high earlier this month, but the stock is plummeting today.That comes after a Wall Street Journal report that is today's overlooked stock. And with more on this story, I'm joined by George Silla, senior markets correspondent. So, this has got a bit of an M&A Monday flavor to it.George, just talk us through it. >> Yeah, well, I think this is interestin ...

And right now we are 2 minutes away from the end of the trading day. Romaine Bostick you're alongside Katie Greipel taking you through to that closing bell with the global simulcast. It starts right now.Carol Massar and Tim Stenovec there. Join us right now as we welcome our audiences across all of our Bloomberg platforms, including television, radio, our partnership with YouTube, the calm after the storm, Carol Massar literally and figuratively when it comes to financial markets right now as we await a ver ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

Merck & Co., Inc. (NYSE:MRK) has reportedly ended discussions to acquire cancer drug developer Revolution Medicines, Inc. (NASDAQ:RVMD) after the two sides disagreed on valuation.Earlier in January, the Financial Times reported that Merck is reportedly in talks to acquire Revolution Medicines in a deal potentially valued at between $28 billion and $32 billion.The talks had valued Revolution Medicines at roughly $30 billion. Citing people familiar with the matter, the Wall Street Journal report on Sunday sig ...

Core Viewpoint - Merck has ceased discussions regarding the acquisition of Revolution Medicines, a company focused on developing cancer drugs, as reported by the Wall Street Journal [1] Company Summary - Merck is a major player in the pharmaceutical industry, known for its extensive portfolio in drug development, including oncology [1] - Revolution Medicines specializes in innovative cancer therapies, indicating a strategic interest in the oncology sector [1] Industry Summary - The oncology drug market continues to attract significant attention from large pharmaceutical companies, highlighting the competitive landscape in cancer treatment development [1] - The cessation of acquisition talks may reflect broader market dynamics or strategic realignments within Merck and its investment priorities in the oncology space [1]

Group 1 - The drugmaker is in discussions to acquire RevMed, a cancer-drug biotech [1] - The potential deal could value RevMed at approximately $30 billion [1]

Company Performance - Halozyme reported strong third-quarter results with record revenue of $354 million, a 22% increase year over year, and earnings per share (EPS) of $1.43, up 36% from the previous year [1] - The company reduced its net long-term debt from $1.5 billion to $800 million, indicating improved fiscal health [1] Revenue Sources - The increase in revenue includes $236 million from royalty revenue, which rose by 52% compared to the same period last year, partly due to the approval of Opdivo for subcutaneous use in Europe [1][2] - Halozyme's Enhanze drug-delivery platform is utilized in 10 drugs, including major cancer therapies like Herceptin and Darzalex Faspro [3] Market Position and Strategy - Halozyme operates as a "pick-and-shovel" stock, focusing on drug-delivery systems rather than therapies, which allows for lower costs compared to many biotech firms [4] - The company is in the process of acquiring Elektrofi, a competitor with a different drug-delivery system, which may enhance its market position [4] Future Outlook - Halozyme forecasts annual revenue between $1.3 billion and $1.375 billion, representing a growth of 28% to 35%, and expects EPS to rise to between $6.10 and $6.50, an increase of at least 44% [8] - The company is well-positioned for growth due to its low debt levels and strong revenue projections, which could provide significant returns for investors [14][15] Industry Context - The biotech sector has shown signs of recovery, with the SPDR S&P Biotech ETF rising 27% in 2025, indicating a positive trend for companies like Halozyme [6] - Both Halozyme and Catalyst Pharmaceuticals are noted for their profitability and relatively low valuations compared to the sector average, suggesting potential for investment [13][14]

"The WomenHeart Summit is a powerful catalyst for elevating women's voices, advancing research, and shaping a future where every woman receives the heart care she deserves." — Nina Goodheart, SVP and President, Structural Heart & Aortic, Medtronic Post this The centerpiece of the Summit will take place on February 2, 2026, featuring the Heart Health IS Women's Health Forum and the Wenger Awards. The Forum, hosted in partnership with HealthyWomen, will bring together clinicians, researchers, advocates, poli ...

Core Viewpoint - Moderna's stock surged 16% following positive clinical trial results for its experimental skin cancer vaccine, mRNA-1893/V940, which showed a 49% reduction in the risk of melanoma recurrence when combined with Keytruda immunotherapy [2][3]. Company Performance - Moderna's revenues have declined at an average annual rate of 52.3% over the last three years, with a 56.4% drop in the latest twelve-month period from $5.1 billion to $2.2 billion [7]. - The most recent quarter reported a 46% year-over-year revenue decline, down to $1.0 billion [7]. - The company is currently trading at a price-to-sales ratio of 7.9x, significantly higher than the S&P 500's 3.3x, indicating that investors are paying nearly $8 for each dollar of revenue generated [6]. Financial Health - Moderna's operating income over the past four quarters was negative $3.5 billion, resulting in an operating margin of -157.3%, compared to the S&P 500's average operating margin of 18.8% [9]. - The company has a solid balance sheet with $734 million in debt against a market capitalization of $19 billion, yielding a debt-to-equity ratio of 4.2% [11]. - Cash and cash equivalents total $4.5 billion out of $12 billion in total assets, resulting in a cash-to-assets ratio of 37.1% [11]. Cash Flow and Sustainability - At the current burn rate of about $2 billion annually in operating cash flow, Moderna has approximately two years of runway before needing to achieve commercial success or raise additional capital [12]. - The company is heavily investing in R&D for its product pipeline while generating minimal revenue from offerings outside of COVID vaccines [10]. Market Resilience - Moderna has shown poor resilience during market declines, with its stock plummeting 85.7% from its peak in August 2021 to November 2023, compared to the S&P 500's 25.4% drop [13]. - The stock has not returned to previous highs and is currently trading near $50 after reaching $166.61 in May 2024 [13]. Investment Outlook - While the cancer vaccine shows promise, it is years away from commercialization and will face regulatory hurdles [8]. - The overall evaluation indicates very weak growth, very weak profitability, very strong financial stability, and weak downturn resilience, suggesting that the risk-reward profile is unfavorable for investors [16].

Group 1 - Revolution Medicines, Inc. (NASDAQ:RVMD) has reportedly attracted takeover interest from Merck, leading to a nearly 46% increase in its stock price [1] - The company is a clinical-stage oncology firm focused on developing targeted therapies for RAS-driven cancers, which are linked to genes that regulate cell growth and division [2] - The biotech sector is characterized by volatility, with significant gains that can quickly reverse, as highlighted by Jim Cramer's comments on the market's frothiness [1] Group 2 - While RVMD shows potential as an investment, there are AI stocks perceived to offer greater upside potential and lower downside risk [3]